A clinical trial involving AstraZeneca’s experimental drug for heart disease has failed to show any benefit, according to results released this week. The trial was designed to test whether the medication could reduce heart-related events or death in patients already taking other treatments. Participants in the study were divided into two groups, with one group receiving the experimental drug and the other a placebo. After more than three years of follow-up, researchers found no significant difference in outcomes between the two groups. Patients who took the drug had a 29% rate of cardiovascular events or death, compared to 32% in those given a placebo. The results were unexpected and have raised concerns among investors and analysts about the future of similar treatments.
Most participants in the trial were already taking another type of medication known as a stabilizer, according to biopharmadive.com. This trial involved a drug called eplontersen, developed by AstraZeneca and Ionis Pharmaceuticals. The medication is meant to stop the production of harmful proteins linked to a rare heart condition called ATTR-CM. The company that makes the drug, Alnylam Pharmaceuticals, also sells a similar treatment called Amvuttra. Analysts have questioned whether adding the silencer drug to existing stabilizer treatments is helpful at all. Some experts believe that combining these types of drugs might not work as well as previously thought.
The trial results may affect how future treatments are designed and tested for this condition. Alnylam’s stock price dropped after the news, reflecting investor concern about the impact on its pipeline. The company is now looking at ways to adjust its next drug development plan, called nucresiran. One suggestion is to focus more on using the new drug as monotherapy rather than in combination with other treatments. Other companies are also testing different approaches to treating ATTR-CM, including drugs that remove amyloid deposits from the body.
The failure of this trial has implications not only for AstraZeneca and Ionis, but also for other drug makers in the field. Companies like BridgeBio, which makes a newer stabilizer, are also affected by these findings. The trial’s broad inclusion criteria may have played a role in the outcome, according to researchers. This study included patients across the full spectrum of disease and treatment history.
The findings suggest that the way treatments are combined may need to be reconsidered in future research. Scientists continue to search for better ways to manage this rare but serious heart condition. The results of this trial may shape how doctors approach treatment for patients with ATTR-CM going forward.
IMAGE: 1202333 / Pixabay